Trial Supports NeuroMetrix Quell For Lower-Back Pain
Executive Summary
Transcutaneous electrical nerve stimulation reduced patients’ reliance on pain drugs over two months.
You may also be interested in...
Clinical Corner: New Data From Xeltis Bioabsorbable Heart Repair Devices Headlines Trial News
Medtech Insight's Clinical Corner highlights recent R&D news and developments in ongoing clinical trials of early, late-stage and approved medical devices. This installment includes news on Abbott's Xience drug-eluting coronary stents, Xeltis' bioabsorbable devices for congenital heart defects, NeuroMetrix's Quell pain therapy, and CytoSorbents' blood purifier to treat inflammation in surgery patients.
NeuroMetrix Brings TENS Pain Therapy To Over-The-Counter Market
NeuroMetrix has launched a non-prescription version of its transcutaneous electrical nerve stimulator (TENS) to overcome some of the limitations put on the technology by reimbursement requirements
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.